C-peptide vs BYM338
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | BYM338 |
|---|---|---|
| Category | Pain Management | Muscle & Performance |
| Full Name | Connecting peptide (C-peptide) | Bimagrumab (BYM338) |
| Molecular Weight | 3020.3 Da | ~148 kDa |
| Half-Life | ~20-30 min | ~2-3 weeks |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | 10-30 mg/kg IV in trials |
| Route | IV|subQ | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 140 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.